Skip to main content
Top
Published in: BMC Psychiatry 1/2013

Open Access 01-12-2013 | Research article

Inhibition/activation in bipolar disorder: validation of the Multidimensional Assessment of Thymic States scale (MAThyS)

Authors: Chantal Henry, Amandine Luquiens, Christophe Lançon, Hélène Sapin, Marcel Zins-Ritter, Stephanie Gerard, Elena Perrin, Bruno Falissard, Michael Lukasiewicz

Published in: BMC Psychiatry | Issue 1/2013

Login to get access

Abstract

Background

One of the major issues in clinical practice is the accurate differential diagnosis between mixed states and depression, often leading to inappropriate prescriptions of antidepressants in mixed states, and as a consequence, increasing the risk of manic switch and suicide. In order to better define the spectrum of mixed states, it may be useful to develop a dimensional approach. In this context, the MAThyS (Multidimensional Assessment of Thymic States) scale was built to assess activation/inhibition levels in all bipolar mood episodes, and to determine whether a clinical description in terms of activation/inhibition can help better define bipolar states with which both manic and depressive symptoms are associated. The aim of this paper is the validation of the MAThyS scale in 141 bipolar patients in acute states (manic, hypomanic, mixed, or depressive).

Methods

The validation of the MAThyS scale was the primary outcome of this 24-week, phase III, open-label, olanzapine single-arm clinical trial. Principal component, factorial analysis, and Cronbach’s coefficient calculation (internal consistency) were performed. Concurrent validity (correlations with 17-item Hamilton Depression Rating Scale [HAMD-17], Hamilton Anxiety Rating Scale [HAMA], and Young Mania Rating Scale [YMRS]) and responsiveness to the clinical intervention were assessed (change in MAThyS scale and effect size) at 6 and 24 weeks.

Results

Scree plot of eigenvalues identified a 2-dimension structure (“activation/inhibition level” and “emotional component”). Psychometric properties were good: Cronbach’s coefficient was >0.9. Concurrent validity was good with low correlation (−0.19) with the HAMA scale and a higher correlation at baseline with the YMRS (0.72) and HAMD-17(−0.43). As expected, the activation state was predominant in manic, hypomanic, and mixed states while inhibition was predominant in depressive states. MAThyS score improvement was observed (effect size: -0.3 at 6 and 24 weeks).

Conclusions

The MAThyS demonstrated good psychometric properties. The MAThyS scale may help clinicians to better discriminate and follow bipolar episodes, especially the broad spectrum of mixed episodes.

Trial registration

ClinicalTrials.gov registration identification number: NCT#002592722
Appendix
Available only for authorised users
Literature
1.
go back to reference Hantouche EG, Akiskal HS, Azorin JM, Châtenet-Duchêne L, Lancrenon S: Clinical and psychometric characterization of depression in mixed mania: a report from the french national cohort of 1090 manic patients. J Affect Disord. 2006, 96: 225-232. 10.1016/j.jad.2005.01.005.CrossRefPubMed Hantouche EG, Akiskal HS, Azorin JM, Châtenet-Duchêne L, Lancrenon S: Clinical and psychometric characterization of depression in mixed mania: a report from the french national cohort of 1090 manic patients. J Affect Disord. 2006, 96: 225-232. 10.1016/j.jad.2005.01.005.CrossRefPubMed
2.
go back to reference Benazzi F, Koukopoulos A, Akiskal HS: Toward a validation of a new definition of agitated depression as a bipolar mixed state (mixed depression). Eur Psychiatry. 2004, 19: 85-90. 10.1016/j.eurpsy.2003.09.008.CrossRefPubMed Benazzi F, Koukopoulos A, Akiskal HS: Toward a validation of a new definition of agitated depression as a bipolar mixed state (mixed depression). Eur Psychiatry. 2004, 19: 85-90. 10.1016/j.eurpsy.2003.09.008.CrossRefPubMed
3.
go back to reference Ghaemi SN, Rosenquist KJ, Ko JY, Baldassano CF, Kontos NJ, Baldessarini RJ: Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry. 2004, 161: 163-165. 10.1176/appi.ajp.161.1.163.CrossRefPubMed Ghaemi SN, Rosenquist KJ, Ko JY, Baldassano CF, Kontos NJ, Baldessarini RJ: Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry. 2004, 161: 163-165. 10.1176/appi.ajp.161.1.163.CrossRefPubMed
4.
go back to reference Rihmer Z, Akiskal H: Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord. 2006, 94: 3-13. 10.1016/j.jad.2006.04.003.CrossRefPubMed Rihmer Z, Akiskal H: Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord. 2006, 94: 3-13. 10.1016/j.jad.2006.04.003.CrossRefPubMed
5.
go back to reference Henry C, M’Bailara K, Mathieu F, Poinsot R, Falissard B: Construction and validation of a dimensional scale exploring mood disorders: MAThyS (Multidimensional Assessment of Thymic States). BMC Psychiatry. 2008, 8: 82-10.1186/1471-244X-8-82.CrossRefPubMedPubMedCentral Henry C, M’Bailara K, Mathieu F, Poinsot R, Falissard B: Construction and validation of a dimensional scale exploring mood disorders: MAThyS (Multidimensional Assessment of Thymic States). BMC Psychiatry. 2008, 8: 82-10.1186/1471-244X-8-82.CrossRefPubMedPubMedCentral
6.
go back to reference Henry C, M’Baïlara K, Poinsot R, Casteret AA, Sorbara F, Leboyer M, Vieta E: Evidence for two types of bipolar depression using a dimensional approach. Psychother Psychosom. 2007, 76: 325-331. 10.1159/000107559.CrossRefPubMed Henry C, M’Baïlara K, Poinsot R, Casteret AA, Sorbara F, Leboyer M, Vieta E: Evidence for two types of bipolar depression using a dimensional approach. Psychother Psychosom. 2007, 76: 325-331. 10.1159/000107559.CrossRefPubMed
7.
go back to reference Henry C, Luquiens A, Lançon C: Activation/Inhibition Response, Efficacy, Safety of Olanzapine in Acute Bipolar Patient: Secondary Outcomes of a 24-Weeks Open-Label Single-Arm Trial. 2010, New Orleans, LA: 163rd APA annual meeting, Abstract NR1-49 Henry C, Luquiens A, Lançon C: Activation/Inhibition Response, Efficacy, Safety of Olanzapine in Acute Bipolar Patient: Secondary Outcomes of a 24-Weeks Open-Label Single-Arm Trial. 2010, New Orleans, LA: 163rd APA annual meeting, Abstract NR1-49
8.
go back to reference Akiskal HS, Hantouche EG, Bourgeois ML, Azorin JM, Sechter D, Allilaire JF, Chatenêt-Duchêne L, Lancrenon S: Toward a refined phenomenology of mania: combining clinician-assessment and self-report in the French EPIMAN study. J Affect Disord. 2001, 67: 89-96. 10.1016/S0165-0327(01)00441-4.CrossRefPubMed Akiskal HS, Hantouche EG, Bourgeois ML, Azorin JM, Sechter D, Allilaire JF, Chatenêt-Duchêne L, Lancrenon S: Toward a refined phenomenology of mania: combining clinician-assessment and self-report in the French EPIMAN study. J Affect Disord. 2001, 67: 89-96. 10.1016/S0165-0327(01)00441-4.CrossRefPubMed
9.
go back to reference Henry C, Luquiens A, Lançon C: Validation de l’échelle “Multidimensional assessment of THYmic states” (Etude MAThyS). LEncéphale. 2010, 36 (Issue 1, Supplement 1): 56-57. Henry C, Luquiens A, Lançon C: Validation de l’échelle “Multidimensional assessment of THYmic states” (Etude MAThyS). LEncéphale. 2010, 36 (Issue 1, Supplement 1): 56-57.
10.
go back to reference Staquet MJ, Hays RD, Fayers PM: Quality of Life Assessment in Clinical Trials: Methods and Practice. 1998, New York: Oxford University Press Staquet MJ, Hays RD, Fayers PM: Quality of Life Assessment in Clinical Trials: Methods and Practice. 1998, New York: Oxford University Press
11.
go back to reference Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003, 60: 1079-1088. 10.1001/archpsyc.60.11.1079.CrossRefPubMed Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003, 60: 1079-1088. 10.1001/archpsyc.60.11.1079.CrossRefPubMed
Metadata
Title
Inhibition/activation in bipolar disorder: validation of the Multidimensional Assessment of Thymic States scale (MAThyS)
Authors
Chantal Henry
Amandine Luquiens
Christophe Lançon
Hélène Sapin
Marcel Zins-Ritter
Stephanie Gerard
Elena Perrin
Bruno Falissard
Michael Lukasiewicz
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2013
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-13-79

Other articles of this Issue 1/2013

BMC Psychiatry 1/2013 Go to the issue